I'm puzzled as well regarding "labeling discussions," especially given recent court cases where generics makers were being pressured to add newly-discovered side-effect info to their labels (which they often discover first when they are the major supplier), yet are required to label their products identically to the originator product when they are therapeutically equivalent.